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INTRODUCTION 
Chronic obstructive pulmonary disease (COPD) remains a major 
public health problem. It is projected to rank fifth in 2020 in burden of 
disease caused worldwide according to WHO study.  
In recent years, importance in understanding and empirical 
management of COPD has increased manifold considering the gravity of 
the situation.  
The concept of cor pulmonale i.e. involvement of right side heart 
usually occurs in COPD. Recently published studies claim that along with 
right side, left heart involvement too occurs resulting in complete heart 
failure.  
Sufficient studies have not been conducted, or since many current 
studies are in process, it has not been proven yet. Percentage of 
documentation of left heart involvement in COPD is not upto the mark in 
India. Thus, the aim of our research is to ascertain the recent findings by 
undertaking a case study of our own among COPD patients. 
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AIM AND OBJECTIVES 
To evaluate the left ventricular systolic and diastolic functions of 
Chronic Obstructive Pulmonary Disease patients using Transthoracic 
Echocardiography. 
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REVIEW OF LITERATURE 
HISTORICAL PERSPECTIVE 
The beginning of modern chest medicine can be traced to the 
classic volume by Laennec, “A treatise on diseases of the chest” which 
appeared in 1821, laid the corner stone of modern chest medicine. 
In his treatise, Laennec, devoted a chapter to “Pulmonary  Catarrh 
or Bronchitis” and emphysema. The chapter on bronchitis distinguishes 
between acute and chronic form and sub divides chronic bronchitis into 
two types  –  the humid (Copious Expectoration) and dry (Scarcely any 
Expectoration). He identified “Dilatation of air cells” as the essential 
feature of emphysema.  
Recognition of chronic bronchitis as a potentially grave illness 
rather than as a trivial one, had to wait the “London Fog” of 1953, which 
was brought about by bad weather and air pollutants, carried with it a 
surge in morbidity and mortality due to chronic lung disease.  
After World War II, clinical investigations of pulmonary disease 
were provided with a new diagnostic armamentarium. Pulmonary 
Function tests were extended beyond simple Spirometry and innovative 
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techniques were developed for assessing the distribution of gases within 
the lungs which greatly improved our understanding of COPD. 
COPD Definition : 
The GOLD guidelines define COPD as “A preventable and 
treatable disease with some significant extra pulmonary effects that may 
contribute to the severity in the individual patient. Its pulmonary 
component is characterized by airflow limitation that is not fully 
reversible. The airflow limitation is usually progressive and associated 
with an abnormal inflammatory response of the lung to noxious particles 
or gases”1. 
Epidemiology : 
Globally, COPD is one of the major cause of morbidity and 
mortality. According to ‘The Global Burden of Disease Study’ COPD is 
expected to become the 3rd most leading cause of death and the 5th 
leading cause of loss of ‘Disability Adjusted Life Years’ (DALYs) in the 
recent future.2 
WHO data on prevalence of COPD is 3.8% in Asian countries. But 
to the contrary, according to recent reports, the prevalence of COPD is 
6.3% in 12-Asian Pacific countries3. 
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The Indian Council of Medical Research (ICMR) took the initiative 
to study the epidemiology of chronic respiratory diseases and sponsored 
the Indian study on Epidemiology of Asthma, Respiratory symptoms and 
Chronic bronchitis (INSEARCH) which included 4-centres in the Phase I 
and 12 other centres in the Phase II study.  
The results of the Phase I study from Chandigarh, Delhi, Kanpur 
and Bangalore reported the overall prevalence rates of 5.0 and 3.2 percent 
in men and women respectively, of and over 35 years of age.4 
RISK FACTORS: 
• Smoking 
• Indoor air pollution 
• Occupational dusts 
• Infection 
• Ageing 
• Genes 
6 
 
 
Smoking has traditionally been known to be the most important 
cause for COPD amounting to almost 85% of the COPD cases (50% 
smokers develop COPD)7,8,9, the rest being classified as non-smoking 
COPD (15%)5,6. 
In developing countries such as India, COPD due to non-smoking 
causes account to 30-50% of all COPD cases10. 
Burning biomass fuel such as wood, cow-dung and crop-residues 
leads to release of air pollutants like SO2, CO, NO2, formaldehyde and 
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particulate matter smaller than 10 micron in size (PM10) in the ambient 
indoor air10,11. Chronic exposure to these pollutants has been shown to 
lead to COPD. 
Another important risk factor for non-smoking COPD is prolonged 
exposure to occupational smoke/dust. 
Tuberculosis is increasingly getting recognized as a risk factor for 
COPD5,6,10. It has been found that even after adequate anti-Koch’s 
therapy in tuberculosis patients, they are 2-6 times more prone to develop 
airway obstruction. Spirometry and insidious onset of symptoms similar 
to COPD in T.B. patients suggest the same. 
Recurrent respiratory infections in childhood have also been shown 
to be associated with development of COPD in adult age5,6,10. 
Physiological lung function decline induced by ageing can also 
predispose to COPD5. 
Genetics come to answer the question why only a fraction of 
smokers develop COPD, while others do not. Perturbation in SERPINA1 
gene leads to deficiency of AAT-1, causing uninhibited action of 
proteases culminating the development of emphysema12. 
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Pathogenesis of COPD 
The cells primarily involved in COPD inflammation are 
neutrophils, macrophages and lymphocytes. The inflammatory cells 
release a battery of inflammatory mediators like cytokines, chemokines 
and chemoattractants which perpetuate the inflammation leading to an 
uncontrollable cascade. 
 
Neutrophils by releasing chemoattractants like interleukin-8 (IL-8) 
and leukotriene B4 (LTB4) attract more neutrophils to the site. 
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Proteolytic enzymes such as elastase, proteinase-3, cathepsin G, cathepsin 
B and matrix metalloproteinases (MMP) released by neutrophils cause 
damage to elastic lung tissue13. 
Macrophages release14 
• cytokines and chemokines such as IL-8, IL-6, IL10, TNFα, 
LTB4 etc which attract and activate various inflammatory cells  
• series of proteinases, particularly MMPs such as MMP-2, 
MMP-9, MMP-12, MMP-14, with tremendous elastolytic 
potential  
• elastinolytic cysteine proteinases such as cathepsin K, L and S. 
• reactive oxygen species 
CD8+ lymphocytes release destructive enzymes such as perforin 
and granzyme B which has the ability to induce apoptosis of the alveolar 
epithelial cells and CD4+ lymphocytes induce autoimmune response 
toward the lung tissue15. 
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Pathophysiology in COPD16,17,18 
Elastin proteolysis 
Elastin proteolysis results in reduction of elastic recoil pressures in 
the lungs moreover since the integrity and movement of air in the 
bronchioles are primarily reliant on elastic recoil pressures induced by 
surrounding elastic tissue, the damage to elastin in COPD results in 
significant airway narrowing with reduction in air flow to the bronchioles 
leading to air trapping in lungs. 
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Fibrotic remodelling 
Fibrotic remodelling of the airways results in fixed airway 
narrowing causing increased airway resistance which does not fully revert 
even with bronchodilators. 
Pulmonary Apoptosis 
Extensive alveolar and bronchiolar epithelial cell damage and 
pulmonary capillary apoptosis are the histological features in emphysema 
and the physiological feature is decreased surface area of alveoli for 
gaseous exchange and ventilation - perfusion mismatch (V/Q). 
Clinical Features 
1. Chronic cough, continuous and productive, increased during 
early morning, may be intermittent and non-productive 
2. Breathlessness on exertion, initially intermittent but later 
becomes persistent 
3. Sputum production of any pattern 
4. Frequent exacerbations of bronchitis 
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5. A history of exposure to risk factors, especially tobacco 
smoke, occupational dusts, home cooking and biomass fuels. 
Systemic Manifestations of COPD19,20,21 
COPD is never a disease of lungs alone. Mortality and morbidity in 
COPD patients is mainly due to the associated comorbities that occurs 
hand in hand with lung dysfunction. The common comorbidities 
associated with COPD are as follows: 
1. Skeletal muscle wasting 
2. Cachexia 
3. Lung cancer (small cell, non-small cell) 
4. Pulmonary hypertension 
5. Ischaemic heart disease: endothelial dysfunction 
6. Congestive cardiac failure 
7. Osteoporosis 
8. Normocytic anaemia 
9. Diabetes mellitus/ Metabolic syndrome 
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10. Obstructive sleep apnoea 
11. Depression 
 
The markers of systemic inflammation that are increased in COPD 
patients are hs C-Reactive Protein (hsCRP), fibrinogen, ferritin, total 
leucocyte count, Reactive Oxygen Species, Interleukins, Transforming 
Growth Factor β1 (TGF-β 1) and Tumor Necrosis Factor-α (TNF-α) and 
other cytokines. 
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COPD and Heart 
The comorbidities occuring in heart of COPD patients are of two 
types. First, diseases that occur because of sharing similar risk factors like 
smoking i.e. Coronary artery disease and Congestive heart failure. Other 
type is the diseases that occur secondary to COPD itself i.e. Secondary 
pulmonary hypertension and Ventricular Dysfunction.  
Traditional teaching is that mortality in early stages of COPD is 
due to cardiovascular disease whereas in late stages, it is due to 
respiratory problems. Coronary artery disease is common in COPD 
patients due to persistent low grade inflammation leading to 
atherosclerosis.22 
Pulmonary arterial hypertension (PAH) in COPD occurs due to 
many reasons23. 
1. Hyperinflation and Alveolar hypoxia 
2. Increased intra thoracic pressure 
3. LV diastolic dysfunction 
Alveolar hypoxia induces pulmonary artery vasoconstriction 
resulting in vascular remodelling which increases pulmonary vascular 
resistance. 
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Rise of intra thoracic pressure due to hyperinflation exceeds the 
venous pressure leading to reduction in blood volume to right and left 
ventricle resulting in increased pulmonary artery wedge pressure. 
LV diastolic dysfunction causes back pressure on the pulmonary 
vasculature and increases pulmonary vascular resistance. 
Chronic pulmonary arterial hypertension increases right ventricular 
after load and results in a clinical syndrome of right heart failure or 
corpulmonale. 
Development of right ventricular hypertrophy and eventual right 
side heart failure is common in COPD. However disturbance in left 
ventricular function has been observed by several workers amongst 
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COPD patients. The left ventricular dysfunction seems to be an aftermath 
of right heart involvement. 
The influence of right ventricular volume/pressure overload on left 
ventricular function is explained by Reverse Bernheim phenomenon24. 
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The predictors of diastolic dysfunction are: 
1. Disproportionate tachycardia 
2. Easy fatigability 
3. Tachypnea 
4. Shortness of breath 
Though patients are asymptomatic even with impaired left 
ventricular function it is exposed when they exercise. Increased demand 
of tissues during exercise elevates the sympathetic drive. The extra 
pressure on the functioning of the heart is not met out due to adverse lung 
function25,26. 
 
18 
 
 
EMP - Endothelial Micro Particles   EC - Endothelial Cell 
INVESTIGATIONS: 
CHEST X RAY: 
Chest X ray shows cardiomegaly in LVF patients with cardio 
thoracic ratio greater than 0.5 but reliability of X ray in COPD patients is 
poor due to hyper inflation.27 
Usually COPD patients have tubular heart. Non tubular heart in  
X-ray of COPD patients should raise the suspicion of diastolic 
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dysfunction. This finding has no relation with FEV1 or increased broncho 
vascular markings. FEV1 
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In chest X ray lateral view obliteration of retro sternal space 
implies right ventricular hypertrophy. 
CT SCAN:  
In mediastinal window, if the pulmonary artery diameter is same as 
the aorta suspect pulmonary artery hypertension. The specificity of this 
finding in CT is 100%. 
 
 
ECG:  
ECG shows right axis QRS deviation, P pulmonale and right 
ventricular hypertrophy. 
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PFT:  
PFT shows decrease in FVC, decrease in FEV1, decrease in 
FEV1/FVC. 
 
Patients with COPD and IC/TLC of less than or equal to 0.25 have 
an impaired LV diastolic filling and impaired global RV function. 
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ECHO:  
LVDD is confirmed by28,29,30 
1. LVEF greater than 50% 
2. LV end diastolic volume index less than 97 mL/m2 
3. Invasively measured LV end diastolic pressure greater than 60 
mmHg 
4. Mean Pulmonary Capillary Wedge Pressure greater than 12 
mmHg 
5. LV chamber relaxation greater than 48 ms 
6. Constant of LV chamber stiffness greater than 0.27 
Global RV function is assessed by Tei’s index or Myocardial 
performance index 
Tei’s index = Isovolumetric contraction time + Isovolumetric 
relaxation time/ Ejection time.  
It is increased in COPD with pulmonary hypertension. 
Miller manoeuvre during 2D ECHO study of normal persons 
shows increased right ventricular loading and acute leftward displacement 
of inter ventricular septum during end diastole end systole.  
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The correlation between LA and LV filling performance with RV 
pressure and diameter is called as Ventricular Interdependence.  
ECHO in COPD patients show inspiratory drop in pleural pressure. 
Increased transmural pressure of LV increases LV afterload and LV 
Ejection Fraction. 
COPD and skeletal muscle wasting 
There is decrease in muscle mass and strength in COPD patients31 
due to  
1. Deconditioning  
2. Disuse atrophy 
3. Systemic inflammation induced protein metabolism 
4. Oxidative stress malnutrition 
Increase in TNF α decreases muscle mass, causes loss of type II A 
muscle fibers32. Systemic oxidative stress also causes the same33. 
Ubiquitin proteasome activation causes active proteolysis and 
muscle wasting34. 
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COPD and Cachexia 
Leptin causes activation of sympathetic nervous system, vascular 
smooth muscle hypertrophy and cardiovascular remodelling. Adiponectin 
has anti leptin effects and is protective. Cachexia in COPD causes 
impaired production of adiponectin and increase leptin effects35,36. 
COPD and Osteoporosis 
Increased prevalence of osteoporosis in COPD patients causes 
increased incidence of vertebral compression fractures. The inflammatory 
mediators, TNF α, IL 1β, IL 6 activate osteoclast and promote bone 
resorption37. 
Prolonged use of steroids results in reduced Osteoprotegrin 
production and upregulates RANK 1 ligand which in turn causes 
osteoclast activation resulting in bone resorption38. Inflammatory 
cytokines also reduce vitamin D levels in COPD patients adding to 
osteoporosis. 
COPD and Depression 
Depression in COPD patients is associated with increased IL 6. 
This is due to loss of independence with increase in disability. Cognitive 
dysfunction also occurs in COPD39,40. 
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COPD and anaemia:  
Normocytic normochromic anaemia occurs in COPD. 
Inflammatory cytokines produced in COPD patients reduce RBC survival 
and increase erythropoietin levels. Conversely, anaemia occurs due to 
peripheral erythropoietic resistance41. 
COPD and lung cancer:  
Risk of lung cancer is increased in COPD due to chronic 
inflammation with increased production of growth factors and angiogenic 
factors like nuclear factor erythroid 2-related factor 2 (Nrf2)42. 
COPD and Metabolic syndrome 
TNF α, IL-6 induce insulin resistance and results in metabolic 
syndrome in COPD patients43,44. 
Treatment of comorbidities 
The primary reason for comorbidities in COPD is pulmonary 
inflammation. Treatment of comorbidities may be divided into two types 
1. Treatment of comorbidities with routine COPD therapy 
2. Treatment of comorbidities per se 
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Treatment of comorbidities with routine COPD therapy 
The available modalities are 
1. Inhaled Corticosteroids 
2. Bronchodilators 
3. Lung volume reduction surgery 
4. Oxygen therapy 
5. Pulmonary rehabilitation 
Inhaled Corticosteroids reduces all-cause mortality in patients with 
COPD45, but there is evidence that ICS either alone or used with LABA  
(long acting β2 agonist) has no role in suppressing systemic inflammation 
associated with COPD46. 
LABA, though no role in inflammation suppression improves 
skeletal muscle mass and prevents fatigue in COPD patients47. Anti 
cholinergics reduce inflammation mediated through mechanical forces of 
the lung causing mechanical strain to epithelial cells48. Theophylline in 
low doses reduce inflammation mediated by neutrophils49. 
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Lung volume reduction surgery improves BMI, metabolic profile, 
osteoporosis, cardiac function, BODE index and long term survival50,51 
Continuous home oxygen therapy and pulmonary rehabilitation 
improves exercise endurance, BODE scores and survival in COPD 
patients52. 
Treatment of comorbidities 
This includes 
1. Statins 
2. ACE inhibitors 
3. PPAR agonists 
Statins despite reducing total cholesterol levels, also have anti-
oxidant, anti-inflammatory, and immune modulatory effects53,54.  
Statins are used in comorbidities like cardiovascular diseases, 
diabetes, osteoporosis and lung cancer55.  
The effects mediated by statins are shown in figure. 
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ACE inhibitors used in heart failure and hypertension reduces 
inflammatory effects mediated through angiotensin II56. 
Reduced expression of PPAR - α and PPAR - γ mRNA is found in 
COPD patients with cachexia.  
PPAR agonists pioglitazone is useful in cachexia, skeletal muscle 
weakness and reducing systemic inflammation57,58. 
They have both anti-inflammatory and immuno modulatory effects. 
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Newer Therapies Under Research 
1. Phospodiesterase 4 inhibitors 
2. P38 Mitogen activated protein kinases 
3. NF-kB inhibitors 
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MATERIALS AND METHODS 
Setting 
The study was conducted in Government Mohan 
Kumaramangalam Medical College, Salem. 
Study Design: 
Cross- sectional study. 
Period of Study: 
 July 2010 to June 2012 
Sample Size: 
50 Cases; 40 Controls 
Study Population: 
Patients admitted in medicine wards of Government Mohan 
Kumaramangalam Medical College, Salem. 
Ethical Committee Clearance:  Obtained 
Conflict Of Interest: Nil 
Financial Support: Nil 
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Case Definition: 
The cases in this study have following characters: 
¾ Cases presenting with symptoms suggestive of chronic airway 
obstruction like cough, cough with expectoration of sputum of 
more than 2 years duration, dyspnoea, and with (or) without 
swelling of both legs. 
¾ Cases in whom clinical diagnosis of COPD was made. 
¾ All the cases were subjected to spirometry and the presence of 
COPD was confirmed by post bronchodilator spirometry 
values of 
i. FEV1 < 80%. 
ii. FEV1 / FVC < 0.7. 
iii. Reversibility of obstruction < 15%. 
(FEV1 – Forced Expiratory Volume in 1 second FVC – Forced 
Vital Capacity) 
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Inclusion Criteria: 
¾ Patients with age greater than 35 years 
¾ Patients with clinical and spirometric evidence suggestive of 
COPD 
Exclusion Criteria: 
¾ Patients with other respiratory diseases like: 
a. Asthma,  
b. Tuberculosis,  
c. Bronchiectasis,  
d. Lung malignancy 
¾ Patients with Cardiac diseases like: 
a. Valvular heart diseases,  
b. Coronary heart diseases,  
c. Hypertension,  
d. Cardiomyopathies 
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¾ Patients with AIDS 
¾ Patients who cannot perform Spirometry or with poor echo 
window 
Controls: 
Age matched, non smoking, healthy volunteers. 
Methods: 
Both cases and controls were subjected to : 
1) History taking and clinical examination. 
2) Routine blood and urine investigations 
3) Sputum AFB 
4) HIV Serology 
5) Chest X-Ray PA View 
6) Electrocardiography 
7) Echocardiography 
8) Spirometry 
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Spirometry 
Spirometry is a method of assessing lung function by measuring 
the volume of air that the patient can expel from the lungs after  maximal 
inspiration. 
The indices derived from forced exhaled manoeuvre have become 
the most accurate and reliable way of supporting a diagnosis of COPD.  
When these values are compared with predicted normal values 
determined on the basis of age, height, sex, and ethnicity, a measure of 
the severity of airway obstruction can be determined. Based on these 
values COPD has been classified as mild, moderate, severe and very 
severe disease levels. 
Its major uses in COPD are to: 
1. Confirm the presence of airway obstruction 
2. Confirm FEV1/FVC ratio of < 0.7 after bronchodilator 
3. Provide an index of disease severity 
4. Help differentiate asthma from COPD 
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5. Detect COPD in subjects exposed to risk factors, 
predominantly tobacco smoke independent of the presence 
of respiratory symptoms 
6. Enable monitoring of disease progression 
7. Help assess response to therapy 
8. Aid in predicting prognosis and long-term survival 
9. Exclude COPD and prevent inappropriate treatment, if 
spirometry is normal 
Procedure of Spirometry 
1. Maximal inspiration 
2. Maximal expiration (“blast” expiration) 
3. Continued expiration until maximal amount of air is exhaled 
(residual volume) (at least a 6 second exhalation in adults) 
4. Get 3 readings –within 5% or 100ml of each other. 
5. Use best values for FEV1,FVC and FEV1/ FVC Ratio. 
 
37 
 
Information Provided by the Spirometer 
• FEV1 (Forced expiratory volume in one second): The volume 
of air exhaled in the first second of the blow. 
• FVC (Forced vital capacity): The total volume of air that can 
be forcibly exhaled in one breath. 
• FEV1/FVC ratio: The fraction of air exhaled in the first 
second relative to the total volume exhaled.   
• The ratio of FEV1/FVC is normally between 0.7 and 0.8. 
Values below 0.7 are a marker of airway obstruction, except in 
older adults where values of 0.65–0.7 may be normal.  
Bronchodilator Reversibility Testing in COPD 
Assessing bronchodilator reversibility is important to determine 
whether fixed airway narrowing is present. In patients with COPD, post-
bronchodilator FEV1/FVC remains < 0.7. However, the FEV1 may 
improve significantly after bronchodilator, and a change of > 12% or 
> 200 mL in FEV1 can occur in COPD. 
1. Spirometry should be undertaken when the patient is 
clinically stable and free from a respiratory tract infection. 
38 
 
2. Short-acting bronchodilators should be withheld for the 
previous 6 hours, long-acting bronchodilators for 12 hours, 
and sustained release of theophylline for 24 hours. 
3. FEV1/FVC should be measured before and 15-20 minutes 
after bronchodilator is given. 
4. The bronchodilator should be given by metered dose inhaler, 
ideally through a spacer. A nebulizer may be used but 
generally larger doses are delivered by this route. 
5. The dose administered should be high on the dose-response 
curve. 
6. Possible dose protocols include 400 μg salbutamol, up to 
160 μg ipratropium, or the two combined. 
Calculating bronchodilator reversibility: 
% FEV1 Reversibility =  
Post-bronchodilator FEV1 – Pre bronchodilator FEV1 x 100 
Pre-bronchodilator FEV1 
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Contraindications:  
Increases Intraocular, Intrathoracic, Intra-abdominal and 
Intracranial pressure 
1. At least 6 weeks since the last exacerbation. 
2. Recent MI less than 3-6 months ago. 
3. Unstable angina in last 24 hours. 
4. Haemoptysis of unknown origin. 
5. Recent eye surgery less than 3-6 months. 
6. Abdominal surgery within last 3-6 months. 
7. Recent CVA less than 3-6 months. 
8. Diagnosis of Tuberculosis unless special precautions used. 
9. Current chest infection or within last 6 weeks. 
10. Current chest pain with no diagnosis. 
11. Pulmonary embolism (PE) within last 3-6 months. 
12. Ear infection. 
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13. Spontaneous pneumothorax. 
14. Aortic aneurysm. 
GOLD COPD Staging 
GOLD divides COPD into four stages based on FEV1% and 
FEV1/FVC% determined by spirometry 
1. Mild 
2. Moderate 
3. Severe 
4. Very severe 
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GOLD COPD STAGING
42 
 
Echocardiography: 
The Doppler echocardiographic examinations were performed 
using a commercially available Doppler echocardiograph and a 
transducer array of 2.5 MHz. Images were obtained from parasternal 
views (long axis and short axis) and apical four-chamber view. 
The subjects were placed in  left lateral decubitus position for the 
parasternal views and in a supine position for the apical four-chamber 
view. Subjects stay at rest for 10 minutes before the Echocardiographic 
examination. 
Right Ventricular Enlargement 
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Parasternal short axis view is used to determine RV enlargement. 
In this view, RV is thin with a cresentric cavity anterior to LV. LV cavity 
is usually rounded. RV cavity is usually smaller than that of LV in cross 
section. 
When RV dilates or hypertrophies : 
1. RV cross section is greater than LV cross section 
2. LV cavity becomes D- shaped rather than rounded 
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Measurement of Systolic Pulmonary Arterial Pressure 
Systolic PAP is equal to right ventricular systolic pressure(RVSP) 
in the absence of right ventricular outflow tract obstruction or pulmonary 
stenosis. 
 
RVSP = Tricuspid pressure gradient(TVpg) + Right atrial 
pressure(RAP) 
TVpg is the pressure gradient across both RA and RV during 
systole and is measured by Bernoulli’s equation. 
Bernoulli equation, TVpg = 4v2 
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‘v’ is the tricuspid regurgitant jet velocity measured in apical 4 
chamber view by placing color wave doppler line placed in the centre of 
the jet. 
Right atrial pressure is assessed by Caval index, IVC collapse with 
respiration. (Complete collapse – 5 mm Hg, Partial collapse – 10 mm Hg, 
No collapse – 15 mm Hg). 
LV systolic function 
Standard indices of global LV systolic performance are  
1. Ejection Fraction (EF) and  
2. LV percent fractional shortening (%FS). 
These indices are usually estimated from various cardiac diameters. 
1. Left ventricle end-systolic and end diastolic diameters 
(LVESD, LVEDD), 
2. Inter ventricular septal thickness (IVS), 
3. Right ventricle end-systolic and end diastolic diameters 
(RVESD, RVEDD) 
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4. Left ventricular posterior wall thickness at end diastole and 
end systole. 
The above indices were measured by M-mode echocardiography 
from the left parasternal short- and long-axis views. 
 
%FS was taken as the ratio of (LVEDD – LVESD)/LVEDD 
EF was determined using the Teichholz formula.  
LV diastolic function. 
The indices used for assessment of LV diastolic function are : 
Mitral inflow patterns 
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1. E/A ratio, 
2. Deceleration time,  
3. Iso volumetric relaxation time (IVRT) 
4. Mitral annulus velocities on tissue doppler: E/e' ratio 
The flow from the left atrium to the left ventricle occurs in 3 
phases: 
I. Initial rush of blood as soon as the valve opens causes  
peaking of velocity in early diastole, the ’E‘ wave. 
II. This is followed by a period of low or no flow, also known 
as diastasis. 
III. In end-diastole, atrial contraction produces a final rush of 
blood into the ventricle, the ’A’ wave. 
This was measured by placing the cursor over the tips of open 
mitral leaflets in apical 2 chamber or 4 chamber view. 
The deceleration time (DT) is the time taken from the maximum E 
point to baseline. 
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IVRT is measured as the time between the closure of the aortic 
valve and the opening of the mitral valve. 
 
In apical 4 chamber view, in tissue Doppler imaging, a 2mm to 
5mm sample volume is placed over the medial mitral annulus, at the base 
of the mitral leaflet. Typically, two negative waves in diastole and one 
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positive wave in systole is seen. The first of the diastolic waves is the 
result of movement of the annulus towards the left atrium during initial 
filling of the LV. This wave is referred to as e'. The second diastolic wave 
is referred to as a'. The systolic wave is labeled as s'. 
 
Diastolic filling abnormalities can be graded as follows: 
Grade 0: Normal diastolic function (E > A) 
Grade 1: Impaired relaxation (E:A reversal i.e. E is < A) 
Grade 2: Pseudonormal (E:A ratio appears normal) 
Grade 3: Restrictive filling (E:A ratio often > 2) 
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Statistical Analysis 
The data collected were scored & analysed using SPSS (Statistical 
Package for Social Science) Ver 16.01. Continuous variables were 
presented as Mean (M) with Standard deviation (sd) and categorical 
variables were presented as frequency and percentages. Student t-test and 
analysis of variance (ANOVA) were used for testing the significance of 
all the variables (Mean & sd) in both groups. Chi-square test was used to 
compare proportions. All the statistical results were considered 
significant at P value < 0.05. 
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OBSERVATION AND RESULTS 
Table - 1 : Sex distribution of the Sample 
Sex 
CASE N=50 CONTROL N=40 
N % N % 
Male 28 56.00 20 50.00 
Female 22 44.00 20 50.00 
Chi-square value 0.32 
Df 1 
p-value 0.57 (Not Significant) 
 
From the above table it is observed that, number of males is 
slightly higher than females in the study group. 
But there was no significant difference in sex between the study 
group and the control group. 
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Table - 2 : Age Distribution of the Study Sample  
 CASE N=50 CONTROL N=40 
N % N % 
35-45 9 18.00 10 25.00 
45-55 28 56.00 11 27.50 
55-65 11 22.00 14 35.00 
65-75 2   4.00 2   5.00 
75-85 0 0 3 7.50 
Mean (sd) 51.94 ± 7.57 55.20 ± 11.34 
T-value 
Df 
p-value 
1.63 
88 
0.11 (Not Significant) 
 
There is no significant difference in age between COPD and 
control group. The minimum age of the patient was considered to be 35 
because COPD is usually a disease of middle age and is less likely below 
35 years. 
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Table-3 : FEV1 
 CASE CONTROL 
Mean 0.98 3.15 
Sd 0.28 0.60 
t-Value 22.73 
Df 88 
p-value 0.000 ( Significant ) 
 
From the above table it is inferred that mean difference in FEV1 in 
the study group is 0.98±0.28 and in control group is 3.15± 0.60. 
By applying student t test, p value was found to be significant 
between the two groups. 
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Table - 4 : FVC 
 CASE CONTROL 
Mean 1.92 3.86 
sd 0.28 0.75 
t-Value 16.76 
Df 88 
p-value 0.000 ( Significant ) 
 
From the above table, it is observed that mean difference in FVC is 
1.92±0.28 in COPD group and 3.86±0.75 in the control group.  
P value was significant between the two groups. 
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Table - 5 : FEV1/FVC 
 CASE CONTROL 
Mean 51.10 81.83 
sd 7.94 4.44 
t-Value 21.86 
Df 88 
p-value 0.000 ( Significant ) 
 
From the above table, it is inferred that mean difference in the 
FEV1/FVC in COPD group was 51.10±7.94 and control group was 
81.83±4.44. p value was significant. 
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Table - 6 : Corpul Monale 
 Case Control 
Number Percentage Number Percentage 
Absent (A) 43 86.00 40 100 
Presented 
(P) 
7 14.00 0  
Total 50 100 40 100 
Chi square 3.07 
Df 1 
P value 0.01 (Significant) 
 
Statistically significant association was found in cor pulmonale in 
COPD group when compared to control group by applying chi square 
test.  
Cor pulmonale was found in 14% of COPD patients 
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Table - 7 : Elevated PAP 
 Case Control 
Number Percentage Number Percentage 
Absent (A) 31 62.00 40 100 
Presented 
(P) 
19 38.00 0  
Total 50 100 40 100 
Chi square 19.27 
Df 1 
P value 0.000 (Significant) 
 
Statistically significant association was found in elevated PAP in 
COPD group when compared to control group. PAP is elevated in 37% of 
the patients 
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Table - 8 : LVDD 
 Case Control 
Number Percentage Number Percentage 
Absent (A) 37 74.00 40 100 
Presented 
(P) 
13 26.00 0 0 
Total 50 100 40 100 
Chi square 12.16 
Df 1 
P value 0.000 (Significant) 
 
Statistically significant association was found in LVDD in COPD 
group when compared with controls.  
LVDD is found in 26% of the COPD patients 
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Table - 9 : LVSD 
 Case Control 
Number Percentage Number Percentage 
Absent (A) 50 100 40 100 
Presented 
(P) 
0 0 0 0 
Total 50 100 40 100 
 
No significant association was found in both COPD and control 
groups. 
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Table - 10 : GOLD COPD STAGING 
 Number Percentage 
Mild 14 28.00 
Moderate 26 52.00 
Severe   6 12.00 
Very Severe   4   8.00 
Total 50 100 
 
From the above table, it is observed that mean difference in the 
majority of patients in the COPD group were in the moderate group 
(FEV1 50-80%) i.e. about 52%. 
8% of patients showed very severe airflow obstruction i.e. GOLD 
stage IV (FEV1<30%). 
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TABLE - 11 : GOLD COPD STAGING vs  CORPUL MONALE 
G C Staging A P 
Number Percentage Number Percentage 
Mild 14 32.60 0  
Moderate 24 55.80 2 28.60 
Severe 4 9.30 2 28.60 
Very Severe 1 2.30 3 42.90 
Total 43 100 7 100 
Chi-square 17.36 
Df 3 
P-Value 0.001 (Significant) 
 
From the above table, it is observed that there is significant 
association between GOLD COPD staging and cor pulmonale.  
The association of cor pulmonale increases with increase in GOLD 
COPD staging. 
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TABLE - 12 : GOLD COPD STAGING vs  Elevated PAP 
G C Staging A P 
Number Percentage Number Percentage 
Mild 11 35.50 3 15.80 
Moderate 18 58.10 8 42.10 
Severe 02 6.50 4 21.10 
Very Severe 0 0 4 21.10 
Total 31 100 19 100 
Chi-square 10.83 
Df 3 
p-value 0.013 
 
From the above table, it is observed that there is significant 
association between GOLD COPD staging and elevated PAP. 
 Association of elevated PAP increases with increase in GOLD 
COPD staging. 
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TABLE - 13 : GOLD COPD STAGING  vs  LVDD 
G C Staging A P 
Number Percentage Number Percentage 
Mild 13 35.10 1 7.70 
Moderate 21 58.00 5 38.50 
Severe 3 08.10 3 23.10 
Very Severe 0 0 4 30.80 
Total 37 100 13 100 
Chi-square 16.39 
Df 3 
p- value 0.001 (Significant ) 
 
From the above table, it is observed that there is significant 
association between GOLD COPD staging and LVDD. 
LVDD can be seen in every stage of COPD.  
Association of LVDD increases with increase in GOLD COPD 
staging. 
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Discussion 
The common cardiac manifestations secondary to COPD are  
1. Cor pulmonale 
2. Elevated PAP  
3. Ventricular dysfunction 
Cor Pulmonale 
Cor pulmonale is found in 14 percent of patients in this study. 
Rigolin et al59 and Fishman et al60 has found that in autopsy, cor 
pulmonale was found in 40 percent of COPD patients. 
Elevated PAP 
In this study, PAP is elevated in 38 percent of COPD patients, but 
the true prevalence of elevated PAP is variable, being about 20-90 
percent, which was proved by various studies using right heart 
catheterization61,62,63. 
Elevated PAP is a prognostic indicator in COPD patients. 
Weitzenblum et al64 has found that 5 year survival rate in patients with 
elevated PAP was 50 percent in mild PHT (20-30 mm Hg), 30 percent in 
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moderate to severe group (30-50 mm Hg) and 0 percent in very severe 
group (>50 mm Hg).  
The frequency of elevated PAP in the study is 16 percent in mild, 
42 percent in moderate, 21 percent in severe and 21 percent in very 
severe. Higham et al65 has found it to be 25 percent, 43 percent and 68 
percent in mild, moderate and severe group.  
In our study, incidence of PHT increases with increase in COPD 
staging. 
Right Ventricular Dysfunction 
Bristow et al66 described that right ventricle is thin-walled and 
eccentric, small increases in pulmonary artery pressure may result in 
large increases in right ventricular work and pulmonary hypertension 
overloads the right ventricle, enlarges right heart chambers and ultimately 
causes right ventricular failure. 
Left Ventricular Dysfunction 
LV functions are usually normal in COPD patients.  
Robotham et al67 has found that LV dysfunction may be due to  
1. Hypoxia and acidosis 
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2. Reverse Bernheim phenomena or ventricular 
interdependence and  
3. Large changes in intrathoracic pressure. (Due to 
hyperinflation, there is increase in negative pleural pressure 
which decreases LV stroke volume and increases afterload.) 
In this study, LV diastolic dysfunction is found in 26 percent in the 
COPD group.  
Louis EK et al68 has demonstrated that probable cause of this LV 
DD is the increase RV volume or pressure which shifts the IVS into the 
LV and compromises the LV contraction, dimensions and compliance. 
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Schena et al69 demonstrated that the right ventricular pressure 
correlates with left ventricular eccentricity indicies; the distorted 
ventricular geometry results in its abnormal filling pattern.  
Butler et al70,71 in his article, ‘Heart in good Hands’ said  that   
“Hyperinflation and distension of lung increases the stiffness of parietal 
pleura and walls of cardiac fossa which adds load to both ventricles and 
contributes to right and left ventricular diastolic dysfunction in COPD 
patients”. 
In this study LV diastolic dysfunction(LVDD) is demonstrated in 
ECHO by E/A ratio and Iso volumetric relaxation time (IVRT). LV 
diastolic dysfunction is predominantly found in patients with elevated 
PAP.  
Boussuger et al72 also obtained similar results in 34 patients with 
moderate to severe COPD using combined analysis of mitral blood flow 
velocities and pulmonary venous blood flow velocities.  
Tutar et al73 described the left ventricular diastolic function 
impairment in COPD patients, and a similar correlation between right 
ventricular pressure, E/A ratio and IVRT were made out. 
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Mustapha et al74 described the relation between right ventricular 
pressure and left ventricular diastolic dysfunction in a large group of cor 
pulmonale patients of different etiology (including COPD patients).  
But Funk et al75 showed that LVDD is found not only in patients 
with increased PAP, but also in normal PAP. It increases with RV 
afterload. 
The elevated LV end diastolic pressure may be transmitted to the 
pulmonary system passively and causes exacerbation of dyspnea. 
LV systolic dysfunction is not impaired in both COPD and control 
group in this study. Similar results were obtained by Schena et al69 and 
Vonk-Noordergrat et al76.  
This shows that unless there is a primary pathology such as 
ischemic heart disease, hypertension etc. affecting LV systolic function, it 
is not compromised in COPD patients.  
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CONCLUSION 
COPD can be considered as a preventable disease taking into 
account the percentage affected among smoking population in India. 
The aim of this research being left ventricular involvement in 
COPD, the data collected from the study conducted that left ventricular 
diastolic function is compromised in COPD patients. Left ventricular 
systolic function remains unaltered even in advanced stages. 
Suspicion and early diagnosis of left ventricular dysfunction in 
COPD is always required, ruling it out by proper evaluation is essential in 
reducing the morbidity. 
Moreover, plethoric research must be conducted on extra 
pulmonary manifestations of COPD for wholesome understanding and 
management of the disease. 
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PROFORMA 
1. DETAILS 
Name: Case No.: 
Age: I.P. No.: 
Sex:                                              Unit: 
Occupation :    D.O.A: 
Address:      D.O.D: 
Socio-economic status :  Poor / Middle class/ Rich 
Education :    Illiterate / Literate 
Locality :    Rural / Urban 
FINAL DIAGNOSIS 
2. INFORMED CONSENT 
I _______________________________ unreservedly and in my full 
sense give 
my full consent to take part in the study of lipoprotein abnormalities in 
chronic 
renal failure. The risks and benefits have been explained to me in my 
vernacularlanguage. 
Date:  
Signature of Patient / Attender 
3. PRESENTING COMPLAINTS 
1. Breathlessness     Yes / No 
2. Cough with expectoration                   Yes / No 
3. Chest pain     Yes / No 
4. Palpitation      Yes / No 
5. Haemoptysis    Yes / No 
6. Fever      Yes / No 
7. Loss of weight    Yes / No 
8. Loss of appetite                          Yes / No 
9. Puffiness of face                                   Yes / No 
10. Swelling of legs                                    Yes / No 
11. Decreased urine output   Yes / No 
4. HISTORY OF PRESENTING COMPLAINTS: 
1. Breathlessness Yes / No 
• Onset: Sudden / Insidious 
• Duration: Hours / Days / Weeks/ Months / Year 
• Present at  Unaccustomed work / Accustomed  
 work/ Routine activity / At rest 
• History of PND  Present / Absent 
• History of Orthopnea Present / Absent 
• History of fatigue  Present/ Absent 
2. Cough Yes / No 
• Duration: Days / Months / Years 
• Onset: Sudden / Gradual 
• Diurnal variation  Present / Absent  
• Postural Variation  Present / Absent 
• Associated features  Wheezing / breathlessness 
3. Expectoration  Present / Absent 
4. Cough Yes / No 
• Amount: Mild / Moderate / Copious 
• Colour: White / Yellow / Greenish / Rusty 
• Smell: Foul Smelling / non foul smelling 
5. Chest Pain  Yes / No 
• Onset: Sudden / Gradual 
• Duration: Hours / Days / Weeks / Months/ Year 
• Site: Precardial / Lateral 
• Type of pain: Squeezing / Pricking / Dull aching /  
 heavy / burning / Catching compressing 
• Severity: Mild / Moderate / Severe 
• Radiation: Left arm / Neck / Abdomen / Back 
• Precipitated by  None / Exertion / Heavy meal 
• Relieved by  Rest / Drugs / None 
6. Palpitation  Yes / no 
• Onset: Sudden / Gradual 
• Duration: Minutes / Hours / days 
• Rhythm: Regular / Irregular 
7. Heamoptysis Present / Absent 
• Amount: Mild / Moderate / Massive 
8. Fever  Yes / No 
• Duration: Days / Weeks / Months 
• Continuous / Intermittent 
• High grade / Low grade 
• Associated features chills / rigors / evening rise of temperature 
9. Loss of weight Yes / No 
10. Loss of appetite  Yes / No 
11. Puffiness of face  Yes / No 
• Duration:  Days / Weeks / Months 
• Diurnal variation: Present / Absent 
12. Swelling of legs 
• Duration:  Days / Weeks / Months 
• Postural variation: Present / Absent 
13. Urine out put 
• Amount:   Polyuria Oliguria / Anuria 
• Duration:  Days / Weeks / Months 
5. PAST HISTORY 
1. History of Tuberculosis     Yes / No 
• Was Under    CAT I / II / III 
• Treatment    Completed / Defaulter 
2. History of Asthma     Yes / No 
3. History of thoracic surgeries    Yes / No 
4. History of hypertension     Yes / No 
5. History of Diabetes Mellitus    Yes / No 
6. History of Heart Disease     Yes / No 
7. History of previous similar episodes   Yes / No 
a. Number of acute exacerbations 
b. Use of inhalers      Yes / No 
c. Use of bronchodilators     Yes / No 
d. Use of Steroids    Yes / No 
6. FAMILY HISTORY 
1. Contact history with Tb    Yes / No 
2. Hypertension    Yes / No 
3. IHD      Yes / No 
4. Diabetes Mellitus    Yes / No 
7. PERSONAL HISTORY 
1. Diet   Vegetarian/Non vegetarian/ Mixed 
2. Smoking  Yes / No 
• No. of Ciggarettes / Beedies per day 
• Duration 
3. Alcoholic   Yes / No 
4. Sleep    Normal / Disturbed 
5. Menstrual history 
• Age of Menarche 
• Cycles 
• Menopause Attained   Yes / No 
8. GENERAL PHYSICAL EXAMINATION 
1. Build    Poorly built / Moderately built / Well built 
2. Nourishment  Poor / Good 
3. Height (Cm) 
4. Weight (Kg) 
5. Body Mass Index (BMI) 
6. Pallor   Yes / No 
7. Polycythemia Yes / No 
8. Icterus   Yes / No 
9. Cyanosis   Yes / No 
10. Clubbing   Yes / No 
11. Pedal Edema Yes / No 
i. Unilateral / Bilateral 
ii. Pitting / Non pitting 
12. JVP     Elevated / Not elevated 
13. Pursed lip breathing Present / Absent 
9. VITAL SIGNS 
1. Pulse 
• Rate 
• Rhythm     Regular / Irregular 
• Volume     Normal / Low / High 
• Character 
• Condition of vessel wall 
• Peripheral pulses   Felt / Not felt 
• Radio femoral delay   Yes / No 
2. Blood Pressure 
3. Respiratory rate 
4. Temperature 
10. SYSTEMIC EXAMINATION 
Respiratory system: 
¾ Upper Respiratory Tract 
o Nose 
o Sinuses 
o Pharynx 
¾ Lower Respiratory Tract 
¾ Inspection 
o Trachea     Right / Left / Central 
o Apical Impulse   Normal / Shifted 
o Movement of Chest Wall  Normal/ Increased/ Decreased 
o Skin over chest wall   Any sinuses / Discharge / Normal 
o Accessory muscles of respiration   Acting / Not acting 
o Dilated veins / Visible pulsation   Yes / No 
o Intercostal retraction     Yes / No 
o Spinal deformities     Yes / No 
¾ Palpation 
o Trachea      Central / Right / Left 
o Apical Impulse    Normal / Shifted 
o Respiratory Movements   Normal / Decreased / Absent 
o Measurements   
 Expansion   Inspiration    Expiration 
Right Hemithorax 
Left Hemithorax 
¾ Localised Swelling   Yes / No 
¾ Intercostal tenderness  Yes /No 
¾ Tactile Fremitus   Normal / Increased / Decreased 
¾ Percussion 
o Lung fields 
 Notes    Resonant / Impaired / Dull 
 Specific Areas 
o Liver dullness in _______ space in Rt. MCL 
o Traubes space obliterated   Yes / No 
¾ Auscultation 
o Breath Sounds 
 Type -    Vesicular / Bronchial / Bronchovesicular 
 Intensity -  Normal / Decreased / Increased 
o Added Sounds – 
 Ronchi 
 Crepitations -     Fine / Coarse 
 Pleural rub -    Yes / No 
 Whispering pectoriloquy -   Yes / No 
 Bronchophony -   Yes / No 
 Succussion splash -    Present / Absent 
CARDIO VASCULAR SYSTEM 
¾ Inspection 
o Shape of Precardium 
o Apical Impulse Location 
o Pulsation present in 
 Aortic Area 
 Pulmonary Area 
 Parasternal Area 
 Epigastrium 
 Carotids 
 Back 
¾ Palpation 
o Mitral area 
 Apex beat 
• Site  and character 
 Palpable Heart sounds 
 Thrills 
o Tricuspid area 
 Left parasternal heave 
 Thrills 
o Aortic area 
 Palpable heart sounds 
 Thrills 
o Pulmonary area 
 Palpable Heart Sounds 
 Thrills 
o Carotid Thrills 
o Epigastric pulsation 
¾ Auscultation 
Areas  SI S2 S3 S4   Murmurs  Added sounds 
Mitral 
Tricuspid 
Aortic 
Pulmonary 
o Pericardial Rub  Yes / No 
ABDOMEN 
¾ Inspection: 
o Shape -    Normal / Distended / Scaphoid 
o Engorged veins - Present / Absent 
o Visible mass -   Present / Absent 
o Visible peristalsis -  Present / Absent 
¾ Palpation: 
o Local rise of temperature -   Present / Absent 
o Tenderness -     Present / Absent 
o Palpable mass -    Present / Absent 
o Organomegaly - 
o Fluid thrill -     Present / Absent 
¾ Percussion: 
o Liver dullness -    Normal / Abnormal 
o Splenic dullness -    Normal / Abnormal 
o Shifting dullness -    Present / Absent 
¾ Auscultation: 
o Bowel sounds -    Normal / Decreased / Absent 
o Venous hum / Arterial bruit -  Absent / Present 
o Splenic rub / Hepatic rub -   Present / Absent 
CENTRAL NERVOUS SYSTEM: 
¾ Higher Mental Functions: 
• Level of consciousness 
• Appearance and behaviour 
• Emotional state 
• Orientation to time / Place / Person 
• Memory - Immediate / Short term / Remote 
• Speech 
• Handedness 
¾ Cranial Nerves: 
  
¾ Motor Functions:  
     Right     Left 
o Tone 
 Upper Limb 
 Lower limb 
o Power 
 Upper Limb 
 Lower Limb 
o Reflexes 
o Superficial 
 Abdominal 
 Cremasteric 
 Plantar 
o Deep Tendon Reflexes 
 Biceps 
 Triceps 
 Supinater 
 Knee 
 Ankle 
¾ Sensory Functions: 
o Superficial - Pain / Touch / Temperature 
o Deep - Vibration / Position / Joint sense  
o Cortical sensation 
¾ Cerebellar signs-    Present / Absent 
¾ Autonomic signs-   Present / Absent 
¾ Signs of meningeal irritation -  Present / Absent 
¾ Gait: 
¾ Peripheral Nerves 
¾ ANY OTHER FINDING 
11. INVESTIGATIONS: 
¾ Blood:  
o Hb%  
o TC  
o DC  
o ESR 
o Blood Urea 
o Serum Creatinine  
o Blood sugar 
¾ Urine:  
o Albumin 
o Sugar   
o Microscopy 
¾ Sputum AFB 
¾ HIV 1 / 2 
¾ Spirometry 
o FEV1 
o FVC 
o FEV1/FVC 
¾ CXR- PA view 
¾ ECG 
¾ ECHOCARDIOGRAPHY 
  
LIST OF ABBREVATIONS 
COPD - Chronic Obstructive Pulmonary Disease 
GOLD - The Global Initiative For Chronic Obstructive Lung 
Disease 
WHO - World Health Organisation 
TNFα - Tumour Necrosis Factor α 
TGF-β  Transforming Growth Factor β 
MMP - Matrix Metalo Proteinases 
LTB4 - Leukotrine B4 
IL-6, 8, 10 - Inter Leukines - 6, 8, 10 
RV, LV - Right Ventricle, Left Ventricle 
IC - Inspiratory Capacity 
TLC - Total Lung Capacity 
FEV1 - Forced Expiratory Volume In 1 Second 
FVC - Forced Vital Capacity 
BODE 
INDEX 
- Body Mass Index, Airflow Obstruction, Dyspnea, 
Exercise Capacity 
ACE - Angiotensin Converting Enzyme 
PPAR - Peroxisome Proliferative Activated Receptor 
PAP - Pulmonary Arterial Pressure 
RVSP - Right Ventricular Systolic Pressure 
TVPG - Tricuspid Pressure Gradient 
RAP - Right Atrial Pressure 
EF - Ejection Fraction 
%FS - % Fractional Shortening 
 
S NO NAME Age Sex FEV1 FVC FEV1/FVC
GOLD COPD 
STAGING
CORPUL 
MONALE
ELEVATED 
PAP LVDD LVSD
1 CHELLAKANNU 45 F 0.7 1.8 44 SEVERE A P P A
2 RAJENDHIRAN 50 M 1.2 2.1 57 MILD A A A A
3 PAAPA 60 F 1 1.8 44 MILD A P A A
4 NAGARAJAN 40 M 1.3 2 68 MILD A A A A
5 SATHYAMOORTHI 42 M 0.8 1.7 77 SEVERE A A A A
6 AYYAKANNU 50 M 0.9 1.9 47 MODERATE P P P A
7 KANDHAYEE 61 F 1.2 2.1 57 MODERATE A A A A
8 AMUTHA 50 F 1 1.8 55 MILD A A A A
9 KRISHNASAMY 39 M 1 1.9 53 MODERATE A P P A
10 ANGAMMAL 50 F 1.1 2.4 48 MILD A A A A
11 LAKSHMANAN 36 M 1.2 2.1 57 MODERATE A A A A
12 KALIANNAN 36 M 0.9 1.8 50 MODERATE A A A A
13 MADHAMMAL 41 F 1.9 2.3 61 MILD A P P A
14 THANGAVEL 49 M 1.1 2.2 50 MODERATE A P A A
15 DHANAKODI 39 F 1 2.1 47 MODERATE A P A A
16 RAJENDIRAN 49 M 1.2 2.1 57 SEVERE P P P A
17 KANNAN 44 M 0.5 1.4 36 VERY SEVERE P P P A
18 BAKKIAYAM 46 F 2.1 3.1 67 MILD A A A A
19 GOVINDAMMAL 50 F 0.8 1.4 57 MILD A A A A
20 ANBARASU  37 M 0.7 1.8 44 MILD A A A A
21 SHANTHA 54 F 1.3 2.3 56 MILD A P A A
22 VENKATESAN 41 M 1 1.8 55 MODERATE A A A A
23 KAMALAM 51 F 1.2 2.1 57 MODERATE A A A A
24 ARUMUGAM 60 M 1 2 50 MODERATE A P A A
MASTER CHART OF STUDY GROUP
S NO NAME Age Sex FEV1 FVC FEV1/FVC
GOLD COPD 
STAGING
CORPUL 
MONALE
ELEVATED 
PAP LVDD LVSD
25 MADAMMAL 60 F 0.9 1.8 50 SEVERE A A A A
26 KANDASAMY 42 M 1 1.8 56 MODERATE A A A A
27 ANTONY RAJ 36 M 1 1.8 55 MODERATE A A A A
28 KAVIARASI 45 F 1 2.2 49 MODERATE A A A A
29 VEDIYAMMAL 40 F 1 1.7 59 MODERATE A P P A
30 KAVERIYAMMAL 42 F 0.9 1.8 50 MODERATE A A A A
31 MUTHARASU 46 M 0.9 2.1 46 MODERATE A A A A
32 ARASAPPAN 36 M 0.9 2.1 46 MODERATE A A A A
33 SHANKAR 52 M 0.7 1.7 41 SEVERE P P P A
34 GANESAN 50 M 1 1.8 56 MODERATE A A A A
35 RAJESWARI 46 F 0.8 1.9 50 SEVERE A P A A
36 KULANDAIVEL  56 M 1.1 2.4 48 MODERATE A A A A
37 JAGANADHAN 57 M 1 1.9 52 MODERATE A P P A
38 ARULMANI 49 F 0.9 1.8 50 MILD A A A A
39 SUNDARAJAN 44 M 0.6 1.6 37 VERY SEVERE A P P A
40 AROKKIYASAMI 59 M 0.7 1.7 38 MILD A A A A
41 ANBALAGAN 74 M 1 1.8 55 MODERATE A A A A
42 IRUSAGOWNDER 75 M 0.7 1.7 41 MILD A A A A
43 MEENAKSHI 51 F 1 1.9 52 MODERATE P P P A
44 RANGANAYAGI 60 F 0.7 1.7 41 VERY SEVERE P P P A
45 VALLI 52 F 1 1.9 52 MODERATE A A A A
46 BASHEER 42 M 1 1.8 55 MODERATE A A A A
47 PALANIYAMMAL 47 F 0.9 1.8 50 MODERATE A A A A
48 BALAJI 45 M 0.6 1.5 40 VERY SEVERE P P P A
49 KANNAPPAN 56 M 0.7 1.8 44 MILD A A A A
50 JAYAMARY 60 F 0.9 1.9 48 MODERATE A A A A
